Literature DB >> 15219191

Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.

P Lollar1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15219191     DOI： 10.1111/j.1538-7836.2004.00802.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  37 in total

1.  Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors.

Authors:  Bhavya S Doshi; Leslie J Raffini; Lindsey A George
Journal:  J Thromb Haemost       Date:  2020-03-02       Impact factor: 5.824

2.  Risk factors for inhibitor formation in haemophilia: a prevalent case-control study.

Authors:  M V Ragni; O Ojeifo; J Feng; J Yan; K A Hill; S S Sommer; M N Trucco; D J Brambilla
Journal:  Haemophilia       Date:  2009-06-26       Impact factor: 4.287

3.  Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.

Authors:  Devi Gunasekera; Ruth A Ettinger; Shelley Nakaya Fletcher; Eddie A James; Maochang Liu; John C Barrett; Janice Withycombe; Dana C Matthews; Melinda S Epstein; Richard J Hughes; Kathleen P Pratt
Journal:  Blood       Date:  2015-01-23       Impact factor: 22.113

4.  Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

Authors:  Joerg Kahle; Aleksander Orlowski; Diana Stichel; John F Healey; Ernest T Parker; Marc Jacquemin; Manuela Krause; Andreas Tiede; Dirk Schwabe; Pete Lollar; Christoph Königs
Journal:  Blood       Date:  2017-05-15       Impact factor: 22.113

5.  Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

Authors:  Joshua I Siner; Benjamin J Samelson-Jones; Julie M Crudele; Robert A French; Benjamin J Lee; Shanzhen Zhou; Elizabeth Merricks; Robin Raymer; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2016-10-06

6.  Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Authors:  Krithika A Shetty; Matthew P Kosloski; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2016-09-13       Impact factor: 1.627

7.  Quantitation of anti-factor VIII antibodies in human plasma.

Authors:  Jolanta Krudysz-Amblo; Behnaz Parhami-Seren; Saulius Butenas; Kathleen E Brummel-Ziedins; Edward D Gomperts; Georges E Rivard; Kenneth G Mann
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

8.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

9.  The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice.

Authors:  John F Healey; Ernest T Parker; Rachel T Barrow; Travis J Langley; William R Church; Pete Lollar
Journal:  Thromb Haemost       Date:  2009-07       Impact factor: 5.249

10.  New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.

Authors:  Ara Metjian; Charles S Abrams
Journal:  Biologics       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.